GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CLS Holdings USA Inc (OTCPK:CLSH) » Definitions » Debt-to-EBITDA

CLSH (CLS Holdings USA) Debt-to-EBITDA : -1,089.25 (As of Aug. 2024)


View and export this data going back to 2014. Start your Free Trial

What is CLS Holdings USA Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

CLS Holdings USA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Aug. 2024 was $2.49 Mil. CLS Holdings USA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Aug. 2024 was $6.22 Mil. CLS Holdings USA's annualized EBITDA for the quarter that ended in Aug. 2024 was $-0.01 Mil. CLS Holdings USA's annualized Debt-to-EBITDA for the quarter that ended in Aug. 2024 was -1,089.25.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for CLS Holdings USA's Debt-to-EBITDA or its related term are showing as below:

CLSH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -34.72   Med: -0.45   Max: 21.93
Current: -34.72

During the past 12 years, the highest Debt-to-EBITDA Ratio of CLS Holdings USA was 21.93. The lowest was -34.72. And the median was -0.45.

CLSH's Debt-to-EBITDA is ranked worse than
100% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs CLSH: -34.72

CLS Holdings USA Debt-to-EBITDA Historical Data

The historical data trend for CLS Holdings USA's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CLS Holdings USA Debt-to-EBITDA Chart

CLS Holdings USA Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.70 -2.47 10.26 -1.53 21.93

CLS Holdings USA Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.15 -12.95 -0.65 0.61 -1,089.25

Competitive Comparison of CLS Holdings USA's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, CLS Holdings USA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CLS Holdings USA's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CLS Holdings USA's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CLS Holdings USA's Debt-to-EBITDA falls into.



CLS Holdings USA Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CLS Holdings USA's Debt-to-EBITDA for the fiscal year that ended in May. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.97 + 6.605) / 0.391
=21.93

CLS Holdings USA's annualized Debt-to-EBITDA for the quarter that ended in Aug. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.491 + 6.223) / -0.008
=-1,089.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Aug. 2024) EBITDA data.


CLS Holdings USA  (OTCPK:CLSH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


CLS Holdings USA Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CLS Holdings USA's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CLS Holdings USA Business Description

Traded in Other Exchanges
Address
516 South, 4th Street, Las Vegas, NV, USA, 89101
CLS Holdings USA Inc is a diversified cannabis company that acts as an integrated cannabis producer and retailer through its Oasis Cannabis subsidiaries in Nevada and plans to expand to other states. CLS stands for Cannabis Life Sciences in recognition of the company's patented proprietary method of extracting various cannabinoids from the marijuana plant and converting them into products with a higher level of quality and consistency. The company's business model includes licensing operations, processing operations, processing facilities, sale of products, brand creation and consulting services. The company generates the majority of its revenues and corresponding accounts receivable from the sale of cannabis, and cannabis related products.
Executives
Frank Koretsky director, 10 percent owner C/O 11767 SOUTH DIXIE HIGHWAY, #115, MIAMI FL 33156
Navy Capital Green Management Llc 10 percent owner, other: See Remark(1) 482 BAYBERRY LANE, MOUNTAINSIDE NJ 07092
Tribeca Investment Partners Pty Ltd 10 percent owner LEVEL 23, 1 O'CONNELL STREET, SYDNEY C3 2000
Ross Silver director 516 SW 13TH STREET, SUITE 201, BEND OR 97702
Andrew Glashow director 1C BOWENS LANDING, NEWPORT RI 02840
David Zelinger director C/O CLS HOLDINGS USA, INC., 11767 SOUTH DIXIE HIGHWAY, SUITE 115, MIAMI FL 33156
Charlene Soco officer: Executive VP of Finance C/O CLS HOLDINGS USA, INC., 11767 SOUTH DIXIE HIGHWAY, SUITE 115, MIAMI FL 33156
Chetan Gulati 10 percent owner 28 REICHERT CIRCLE, WESTPORT CT 06880
Todd V Swanson 10 percent owner 10120 W. FLAMINGO ROAD, #4333, LAS VEGAS NV 89147
Gregg E. Carlson officer: Chief Financial Officer 2342 MALAGA PEAK STREET, LAS VEGAS NV 89135
Navy Capital Green Co-invest Partners Llc 10 percent owner, other: See Remark(1) 28 REICHERT CIRCLE, WESTPORT CT 06880
Navy Capital Green Co-invest Fund, Llc 10 percent owner 28 REICHERT CIRCLE, WESTPORT CT 06880
Navy Capital Green Management Partners Llc 10 percent owner 28 REICHERT CIRCLE, WESTPORT CT 06880
John Kaden 10 percent owner 28 REICHERT CIRCLE, WESTPORT CT 06880
Sean Stiefel 10 percent owner 28 REICHERT CIRCLE, WESTPORT CT 06880